CR20210077A - Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa - Google Patents

Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa

Info

Publication number
CR20210077A
CR20210077A CR20210077A CR20210077A CR20210077A CR 20210077 A CR20210077 A CR 20210077A CR 20210077 A CR20210077 A CR 20210077A CR 20210077 A CR20210077 A CR 20210077A CR 20210077 A CR20210077 A CR 20210077A
Authority
CR
Costa Rica
Prior art keywords
heterocyclic compounds
new heterocyclic
lipase inhibitors
monoacylglycerol lipase
compounds
Prior art date
Application number
CR20210077A
Other languages
English (en)
Inventor
Joerg Benz
Martin Ritter
Carsten Kroll
Hans Richter
Martin Kuratli
Didier Rombach
Bernd Kuhn
Uwe Grether
Marius Daniel Rinaldo Lutz
Benoit Hornsperger
Zbinden Katrin Groebke
Buelent Kocer
Fionn O`Hara
Charles Bell
Luca Gobbi
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20210077A publication Critical patent/CR20210077A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

<p>La invención proporciona nuevos compuestos heterocíclicos que presentan la fórmula general (I) en donde A, L, X, m, n, R1 y R2 son como se describe en la presente, composiciones que incluyen los compuestos, procesos de fabricación de los compuestos y métodos de utilización de los compuestos.</p>
CR20210077A 2018-08-13 2019-08-12 Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa CR20210077A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18188681 2018-08-13
PCT/EP2019/071520 WO2020035424A1 (en) 2018-08-13 2019-08-12 New heterocyclic compounds as monoacylglycerol lipase inhibitors

Publications (1)

Publication Number Publication Date
CR20210077A true CR20210077A (es) 2021-03-11

Family

ID=63244467

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210077A CR20210077A (es) 2018-08-13 2019-08-12 Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa

Country Status (33)

Country Link
US (4) US20200308190A1 (es)
EP (2) EP3837263B1 (es)
JP (2) JP7637049B2 (es)
KR (1) KR102879259B1 (es)
CN (1) CN112867720A (es)
AR (1) AR116666A1 (es)
AU (1) AU2019322538B2 (es)
BR (1) BR112021002298A2 (es)
CA (1) CA3104928A1 (es)
CL (1) CL2021000362A1 (es)
CO (1) CO2021002382A2 (es)
CR (1) CR20210077A (es)
DK (1) DK3837263T3 (es)
ES (1) ES2986417T3 (es)
FI (1) FI3837263T3 (es)
HR (1) HRP20241201T1 (es)
HU (1) HUE067912T2 (es)
IL (1) IL279173B2 (es)
LT (1) LT3837263T (es)
MA (1) MA53219B1 (es)
MX (1) MX2021001433A (es)
MY (1) MY210507A (es)
PE (1) PE20211089A1 (es)
PH (1) PH12021500013A1 (es)
PL (1) PL3837263T3 (es)
PT (1) PT3837263T (es)
RS (1) RS65912B1 (es)
RU (1) RU2769507C1 (es)
SG (1) SG11202013064WA (es)
SI (1) SI3837263T1 (es)
TW (1) TWI812770B (es)
UA (1) UA127629C2 (es)
WO (1) WO2020035424A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR114136A1 (es) 2017-10-10 2020-07-29 Hoffmann La Roche Compuestos heterocíclicos
WO2019105915A1 (en) 2017-11-28 2019-06-06 F. Hoffmann-La Roche Ag New heterocyclic compounds
WO2019134985A1 (en) 2018-01-08 2019-07-11 F. Hoffmann-La Roche Ag Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
BR122023024273A2 (pt) 2018-02-27 2024-02-20 Incyte Corporation Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
AU2019297361B2 (en) 2018-07-05 2024-06-27 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
AU2019322538B2 (en) * 2018-08-13 2021-09-30 F. Hoffmann-La Roche Ag New heterocyclic compounds as monoacylglycerol lipase inhibitors
PL3883936T3 (pl) 2018-11-22 2023-11-20 F. Hoffmann-La Roche Ag Nowe związki heterocykliczne
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
AU2020343737A1 (en) * 2019-09-05 2022-03-31 Lunan Pharmaceutical Group Corporation MAGL inhibitor, preparation method therefor and use thereof
US20210094971A1 (en) * 2019-09-09 2021-04-01 Hoffmann-La Roche Inc. Heterocyclic compounds
MX2022002311A (es) 2019-09-12 2022-03-25 Hoffmann La Roche Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl).
EP4034239A1 (en) * 2019-09-23 2022-08-03 F. Hoffmann-La Roche AG Heterocyclic compounds
AU2020354414A1 (en) * 2019-09-24 2022-02-17 F. Hoffmann-La Roche Ag New heterocyclic monoacylglycerol lipase (MAGL) inhibitors
BR112022003357A2 (pt) * 2019-09-24 2022-05-17 Hoffmann La Roche Compostos heterocíclicos
EP4041229A4 (en) * 2019-10-07 2023-10-25 D.E. Shaw Research, LLC Arylmethylene heterocyclic compounds as kv1.3 potassium shaker channel blockers
CA3176113A1 (en) * 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Aminocyclobutanes as monoacylglycerol lipase modulators
CR20230115A (es) 2020-09-03 2023-04-11 Hoffmann La Roche Compuestos heterocíclicos
IL313987A (en) 2021-12-29 2024-08-01 Psy Therapeutics Inc Inhibiting monoacylglycerol lipase (magl)
KR20250060956A (ko) 2022-08-05 2025-05-07 컴쿼트 바이오사이언시즈 인크. 헤테로환 화합물 및 이의 용도
WO2024168426A1 (en) 2023-02-13 2024-08-22 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214038A (en) 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
US7579495B2 (en) 2003-12-19 2009-08-25 Momentive Performance Materials Inc. Active-releasing cyclic siloxanes
US7842810B2 (en) 2005-03-31 2010-11-30 Janssen Pharmaceutica, Nv Bicyclic pyrazole compounds as antibacterial agents
EP1896453B1 (en) 2005-06-20 2009-12-02 Schering Corporation Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists
JP5116687B2 (ja) 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤
WO2007098418A1 (en) 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Compounds having 5-ht6 receptor affinity
WO2007117557A2 (en) 2006-04-05 2007-10-18 Vitae Pharmaceuticals, Inc. Diaminopropanol renin inhibitors
CA2679754C (en) 2007-03-12 2018-08-07 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
FR2915197B1 (fr) * 2007-04-18 2009-06-12 Sanofi Aventis Sa Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique.
TW200942537A (en) 2008-02-01 2009-10-16 Irm Llc Compounds and compositions as kinase inhibitors
US8394792B2 (en) 2008-03-31 2013-03-12 C&C Research Laboratories Heterocyclic derivatives
CA2741153A1 (en) 2008-10-29 2010-05-06 F. Hoffmann-La Roche Ag Novel phenyl amide or pyridyl amide derivatives and their use as gpbar1 agonists
CA2773182A1 (en) 2009-09-10 2011-03-17 F. Hoffmann-La Roche Ag Inhibitors of jak
WO2011059118A1 (ko) 2009-11-10 2011-05-19 Kim Hyun Jeen 후각인지능력 검사 시스템
US9051296B2 (en) * 2009-11-16 2015-06-09 Raqualia Pharma Inc. Aryl carboxamide derivatives as TTX-S blockers
US8420661B2 (en) 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
JP6254075B2 (ja) 2011-05-16 2017-12-27 バイオノミックス リミテッド カリウムチャネル遮断剤としてのアミン誘導体
WO2013059118A1 (en) 2011-10-19 2013-04-25 The Trustees Of Columbia University In The City Of New York Cyclopropenimine catalyst compositions and processes
EP2785721A1 (en) 2011-11-30 2014-10-08 Actelion Pharmaceuticals Ltd. 3,7-disubstituted octahydro-2h-pyrido[4,3-e][1,3]oxazin-2-one antibiotics
MY170922A (en) 2011-12-22 2019-09-18 Novartis Ag Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
MX350788B (es) 2012-01-06 2017-09-13 Abide Therapeutics Inc Compuestos de carbamato y preparación y uso de los mismos.
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫－吡啶并－□衍生物之固體形式
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 Ｐ２ｘ７調節劑
EA029361B1 (ru) 2013-04-16 2018-03-30 Идорсиа Фармасьютиклз Лтд Антибактериальные биароматические производные
WO2016109501A1 (en) 2014-12-30 2016-07-07 Karos Pharmaceuticals, Inc. Amide compounds as tryptophan hydroxylase inhibitors
WO2016158956A1 (ja) 2015-03-30 2016-10-06 武田薬品工業株式会社 複素環化合物
CN107635986A (zh) 2015-05-13 2018-01-26 赛尔维他股份公司 取代的喹喔啉衍生物
CA2986199C (en) 2015-05-21 2023-07-18 Glaxosmithkline Intellectual Property Development Limited Benzoimidazole derivatives as pad4 inhibitors
MX379846B (es) 2015-06-18 2025-03-11 89Bio Ltd Derivados de 4-bencil y 4-benzoil piperidina sustituidos.
HK1249101A1 (zh) 2015-07-31 2018-10-26 辉瑞公司 作为magl抑制剂的1，1，1-三氟-3-羟基丙-2-基氨基甲酸酯衍生物及1，1，1-三氟-4-羟基丁-2-基氨基甲酸酯衍生物
WO2017087863A1 (en) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
WO2017087858A1 (en) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
MY194647A (en) 2016-03-31 2022-12-09 Takeda Pharmaceuticals Co Heterocyclic compound
US10610520B2 (en) 2016-03-31 2020-04-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
KR20190022728A (ko) 2016-06-30 2019-03-06 바실리어 파마슈티카 인터내셔널 리미티드 증식 장애의 치료를 위한 미토콘드리아 억제제
PE20191239A1 (es) 2016-11-16 2019-09-16 Abide Therapeutics Inc Formas cristalinas de un inhibidor de magl
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
MX394645B (es) 2017-06-12 2025-03-21 Boehringer Ingelheim Int Compuestos heteroaromáticos como inhibidores de vanina.
JP7189143B2 (ja) 2017-09-29 2022-12-13 武田薬品工業株式会社 複素環化合物
AR114136A1 (es) 2017-10-10 2020-07-29 Hoffmann La Roche Compuestos heterocíclicos
WO2019105915A1 (en) 2017-11-28 2019-06-06 F. Hoffmann-La Roche Ag New heterocyclic compounds
TW201930300A (zh) 2017-12-15 2019-08-01 瑞士商赫孚孟拉羅股份公司 新雜環化合物
WO2019134985A1 (en) 2018-01-08 2019-07-11 F. Hoffmann-La Roche Ag Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
MX2020008894A (es) 2018-03-22 2020-10-12 Hoffmann La Roche Inhibidores de oxazin monoacilglicerol lipasa (magl).
AU2019322538B2 (en) 2018-08-13 2021-09-30 F. Hoffmann-La Roche Ag New heterocyclic compounds as monoacylglycerol lipase inhibitors
WO2020035425A1 (en) 2018-08-13 2020-02-20 F. Hoffmann-La Roche Ag New heterocyclic compounds as monoacylglycerol lipase inhibitors
PL3883936T3 (pl) 2018-11-22 2023-11-20 F. Hoffmann-La Roche Ag Nowe związki heterocykliczne
CU20210042A7 (es) 2018-11-22 2022-01-13 Qilu Regor Therapeutics Inc Compuestos agonistas de glp-1r y composiciones farmacéuticas que lo contienen
WO2020207941A1 (en) 2019-04-09 2020-10-15 F. Hoffmann-La Roche Ag Heterocyclic compounds as inhibitors of monoacylglycerol lipase (magl)
JP7669299B2 (ja) 2019-07-03 2025-04-28 エフ． ホフマン－ラ ロシュ アーゲー 複素環モノアシルグリセロールリパーゼ（ｍａｇｌ）阻害剤
JP7649283B2 (ja) 2019-07-09 2025-03-19 エフ． ホフマン－ラ ロシュ アーゲー 新規複素環化合物
US20210094971A1 (en) 2019-09-09 2021-04-01 Hoffmann-La Roche Inc. Heterocyclic compounds
JP2022548018A (ja) 2019-09-12 2022-11-16 エフ．ホフマン－ラ ロシュ アーゲー 放射性標識化合物
MX2022002311A (es) 2019-09-12 2022-03-25 Hoffmann La Roche Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl).
EP4034239A1 (en) 2019-09-23 2022-08-03 F. Hoffmann-La Roche AG Heterocyclic compounds
BR112022003357A2 (pt) 2019-09-24 2022-05-17 Hoffmann La Roche Compostos heterocíclicos
EP4034602A1 (en) 2019-09-24 2022-08-03 F. Hoffmann-La Roche AG Fluorescent probes for monoacylglycerol lipase (magl)
AU2020354414A1 (en) 2019-09-24 2022-02-17 F. Hoffmann-La Roche Ag New heterocyclic monoacylglycerol lipase (MAGL) inhibitors
CN116096723A (zh) 2020-08-26 2023-05-09 豪夫迈·罗氏有限公司 用作magl抑制剂的杂环化合物
CR20230115A (es) 2020-09-03 2023-04-11 Hoffmann La Roche Compuestos heterocíclicos
KR20240000574A (ko) 2021-04-23 2024-01-02 에프. 호프만-라 로슈 아게 헤테로시클릭 화합물

Also Published As

Publication number Publication date
AR116666A1 (es) 2021-06-02
RS65912B1 (sr) 2024-10-31
MA53219A (fr) 2021-11-17
CA3104928A1 (en) 2020-02-20
JP2021534139A (ja) 2021-12-09
WO2020035424A1 (en) 2020-02-20
PE20211089A1 (es) 2021-06-14
FI3837263T3 (fi) 2024-09-03
US20260022130A1 (en) 2026-01-22
TW202021970A (zh) 2020-06-16
JP7637049B2 (ja) 2025-02-27
US12281124B2 (en) 2025-04-22
SI3837263T1 (sl) 2024-10-30
US20230050901A1 (en) 2023-02-16
US20200308190A1 (en) 2020-10-01
TWI812770B (zh) 2023-08-21
AU2019322538A1 (en) 2021-01-07
HUE067912T2 (hu) 2024-11-28
JP2024174966A (ja) 2024-12-17
DK3837263T3 (da) 2024-09-09
CL2021000362A1 (es) 2021-07-09
EP4474017A3 (en) 2025-02-26
AU2019322538B2 (en) 2021-09-30
SG11202013064WA (en) 2021-01-28
US20240150373A1 (en) 2024-05-09
UA127629C2 (uk) 2023-11-08
PH12021500013A1 (en) 2021-09-13
PL3837263T3 (pl) 2024-10-14
KR102879259B1 (ko) 2025-10-31
ES2986417T3 (es) 2024-11-11
US11802133B2 (en) 2023-10-31
KR20210045992A (ko) 2021-04-27
HRP20241201T1 (hr) 2024-11-22
MX2021001433A (es) 2021-04-12
EP3837263A1 (en) 2021-06-23
LT3837263T (lt) 2024-09-25
CO2021002382A2 (es) 2021-03-08
RU2769507C1 (ru) 2022-04-01
PT3837263T (pt) 2024-08-30
MA53219B1 (fr) 2024-09-30
EP3837263B1 (en) 2024-07-03
MY210507A (en) 2025-09-28
IL279173A (en) 2021-01-31
EP4474017A2 (en) 2024-12-11
IL279173B1 (en) 2025-01-01
BR112021002298A2 (pt) 2021-05-04
IL279173B2 (en) 2025-05-01
CN112867720A (zh) 2021-05-28

Similar Documents

Publication Publication Date Title
PH12021500013A1 (en) New heterocyclic compounds as monoacylgylcerol lipase inhibitors
PH12021500015A1 (en) New heterocyclic compounds as monoacylglycerol lipase inhibitors
PH12021551167A1 (en) New heterocyclic compounds
CR20200416A (es) Nuevos compuestos heterocíclicos
PH12022550472A1 (en) New heterocyclic monoacylglycerol lipase (magl) inhibitors
PH12022550339A1 (en) 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors
MX2021014441A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
PH12021553018A1 (en) New egfr inhibitors
PH12022550471A1 (en) Heterocyclic compounds
ZA202005326B (en) Heteroaryl compounds as type ii irak inhibitors and uses hereof
PH12017502090A1 (en) Heterocyclic amides as kinase inhibitors
PH12022550433A1 (en) Heterocyclic compounds
PH12022550321A1 (en) 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors
MX2018001890A (es) Compuestos biciclicos como inhibidores de autotaxina (atx).
PH12021553249A1 (en) New heterocyclic compounds
MX2025015277A (es) Inhibidores de masp-2 y metodos de uso
ZA202309446B (en) Rapamycin analogs and uses thereof
PH12019500664B1 (en) New isoxazolyl ether derivatives as gaba a alpha5 pam
MX377277B (es) Derivados de fenoximetilo.
EP4706394A3 (en) Use of alkoxypyrazoles as nitrification inhibitors
MX2022006776A (es) Composiciones farmaceuticas oftalmicas.
PH12020500674A1 (en) New isoxazolyl ether derivatives as gaba a alpha5 pam
PH12021550320A1 (en) Bicyclic heteroaryl derivatives
WO2021249904A3 (en) Amino-pyrimidine cyclo-amides
PH12018500406A1 (en) Bicyclic compounds as atx inhibitors